Study of glatiramer acetate 40 mg versus oral disease-modifying-therapies for multiple sclerosis

Trial Profile

Study of glatiramer acetate 40 mg versus oral disease-modifying-therapies for multiple sclerosis

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Oct 2016

At a glance

  • Drugs Glatiramer acetate (Primary) ; Dimethyl fumarate; Fingolimod; Teriflunomide
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Oct 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top